Kazia Therapeutics
KZIA | NASDAQ
$5.60
-$1.02 (-15.41%)
At close: Nov 16, 2026, 4:00 PM ET
$5.60
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:46 PM ET
-15.41%
(1D)No price chart data available for 1D timeframe.
Rating
45
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #390/1021 (Top 38%)
Key Statistics
Market Data
Market Cap $17.47M
1D Range
5.43 6.69
52W Range
5.00 16.90
Valuation (TTM)
PE -0.84
PB 0.56
EV/EBITDA 2.37
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $32.00
Cash Flow
FCF Yield -35.0%
SBC Adj. FCF Yield -35.0%
SBC Impact N/A
Margins
Gross Margin 100.0%
Operating Margin -92086.4%
FCF Margin -46038.4%
Growth (CAGR)
Revenue 3Y | 5Y -75.2% |
-63.8%
Dil EPS 3Y | 5Y 71.7% |
29.5%
FCF 3Y | 5Y -4.2% |
-2.7%
Returns
ROA -31.4%
ROE -116.9%
ROIC -36.2%
Financial Health
Net Cash
A$69.29M ($46.24M)
Current Ratio 2.87
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, br...
Sector Healthcare
Industry Biotechnology
Employees 6
IPO Date Jan 6, 1999
Website www.kaziatherapeutics.com
Fiscal Year July - June
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$32.00
Upside
+471.43%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove KZIA